Baker BROS. Advisors LP Takes Position in Maplight Therapeutics, Inc. $MPLT

Baker BROS. Advisors LP acquired a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 364,705 shares of the company’s stock, valued at approximately $6,406,000. Baker BROS. Advisors LP owned about 0.80% of Maplight Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Fcpm Iii Services B.V. bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at about $56,672,000. T. Rowe Price Investment Management Inc. bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at about $49,154,000. Goldman Sachs Group Inc. bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at about $34,026,000. Nan Fung Group Holdings Ltd bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at about $17,060,000. Finally, 5AM Venture Management LLC purchased a new stake in Maplight Therapeutics during the 4th quarter valued at $16,687,000.

Wall Street Analyst Weigh In

MPLT has been the subject of several analyst reports. Lifesci Capital raised shares of Maplight Therapeutics to a “strong-buy” rating in a research report on Thursday, May 14th. Wall Street Zen cut shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. TD Cowen initiated coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating for the company. UBS Group initiated coverage on shares of Maplight Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $48.00 price target for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $37.78.

Maplight Therapeutics Stock Up 7.5%

MPLT opened at $29.21 on Thursday. The stock has a market cap of $1.24 billion and a PE ratio of -0.71. The business has a 50 day moving average of $28.69 and a 200-day moving average of $21.84. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). Equities analysts anticipate that Maplight Therapeutics, Inc. will post -5.04 EPS for the current year.

Insider Activity at Maplight Therapeutics

In other news, insider Erin Pennock Foff sold 24,052 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total transaction of $691,735.52. Following the sale, the insider owned 350,497 shares in the company, valued at $10,080,293.72. This represents a 6.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher A. Kroeger sold 118,235 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the sale, the chief executive officer owned 1,394,094 shares in the company, valued at approximately $37,905,415.86. The trade was a 7.82% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 495,244 shares of company stock worth $14,079,461 over the last quarter. 3.80% of the stock is currently owned by company insiders.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.